Abstract
Clinical heterogeneity represents a great challenge for cancer therapeutics. Molecular classification of patients into different subtypes based on genetic or epigenetic characteristics has the potential to revolutionize the clinical care and mechanistic understanding of a wide spectrum of cancers, including endometrial carcinoma, the most common gynecological cancer affecting women.
Original language | English (US) |
---|---|
Pages (from-to) | 1-3 |
Number of pages | 3 |
Journal | Expert review of anticancer therapy |
Volume | 15 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2014 |
Keywords
- CTNNB1 mutation
- cancer therapeutics
- endometrial carcinoma
- molecular subtyping
- wnt signaling pathway
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
MD Anderson CCSG core facilities
- Bioinformatics Shared Resource